Sanjivani Paranteral Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 9 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹235 Cr
FY'27 total revenue guidance: INR 80-85 crores from base business; INR 60-65 crores from Pune IV plant. For FY'27, base business EBITDA margins are expected in the range of 15.5% to 16.5%, with anticipated recovery from Q1 onwards after March shipment disruptions.
From Sanjivani Paranteral Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹193
Market Cap
₹235 Cr
P/E Ratio
35.2
How does Sanjivani Paranteral Ltd rank in Pharmaceuticals & Biotechnology?
Compare Sanjivani Paranteral Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Sanjivani Paranteral Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹11 Cr, net profit ₹1 Cr.
Full financials →📊 Revenue & Sales Performance
- →FY'27 total revenue guidance: INR 80-85 crores from base business; INR 60-65 crores from Pune IV plant.
- →Base business expected to grow steadily with export operations normalizing and continued expansion in export markets.
- →Injectable segment growth: 10%-12% expected.
- →Tablet segment growth: 7%-8% expected, with increasing product dossiers and portfolio expansion over 2-3 years.
- →Nutraceutical business to ramp up gradually with improved traction in FY'27.
- →Pune IV plant ramp-up: production to increase to 70% utilization by Q4 FY'27, aiming for INR 60 crores annual revenue.
- →Long-term: steady increase in injectable and substantial growth in tablets and capsules expected over next 2-3 years.
- →Growth impacted recently by geopolitical and logistical challenges, but alternative routes established to support recovery.
📈 Profitability & Margins
- →For FY'27, base business EBITDA margins are expected in the range of 15.5% to 16.5%, with anticipated recovery from Q1 onwards after March shipment disruptions.
- →The new Pune IV infusion plant aims for an annual revenue of around INR 60-65 crores with EBITDA margins of 17% to 18%, expected to ramp up utilization from 40% in Q1 to 70% in Q4 FY'27.
- →PAT margins will mirror EBITDA margin improvements as higher-margin products enter the portfolio.
- →The nutraceutical venture (Prague-based) is expected to show improved commercial traction and contribute profits in FY'27.
- →Overall, FY'27 is expected to be stronger with growth and margin expansion driven by all three verticals: base injectable business, IV infusion plant, and nutraceuticals.
- →Management remains optimistic about medium to long-term earnings growth fueled by export market expansion and new product approvals.
🏗️ Capital Expenditure Plans
- →The company has recently commissioned a new IV fluid infusion plant in Pune, which started commercial production in December 2025.
- →The Pune plant has an annual installed capacity of 60 million bottles, with ramp-up expected to reach 70% utilization by Q4 FY '27.
- →Expected revenue from the Pune IV plant for FY '27 is around INR 60-65 crores with EBITDA margins of 17-18%.
- →There is ongoing work on dossier filings and approvals for new products, including those for the Pune plant; pipeline approvals were expected by early 2026 but delayed due to regulatory changes.
- →The company is also invested in Prague Ventures (nutraceuticals), owning 45% with plans to increase stake to majority in the future; commercial activities and revenue growth expected in FY '27.
- →No explicit mention of further large-scale new capex was noted beyond this ongoing plant scale-up and portfolio expansion.
💰 Fundraising & Capital Structure
- →The transcript does not mention any current or planned fundraising through debt or equity.
- →No discussions or questions related to raising capital via equity or debt instruments were addressed during the call.
- →The focus was primarily on operational performance, margin guidance, scale-up of the Pune IV plant, and geographic/product portfolio expansion.
- →The company emphasized improving margins, scaling new product lines, and managing working capital internally without indicating external fund-raising plans.
📋 Order Book & Pipeline
- →Pune IV facility currently has 5 product approvals and 18 products in the pipeline.
- →Approval delays have occurred due to government staff transfers and stricter approval processes.
- →A significant portion of approvals (a "quite chunk") is expected to be received in the current month (May 2026).
- →Out of the 18 products in the pipeline for the Pune plant, about 6 are expected to contribute to revenue.
- →Pune IV plant is targeting around INR 60 crore in annual revenue, reflecting a ramp-up and commercial scale-up of new products.
- →The nutraceutical venture (Prague Ventures) is ramping up with a good order book in the current year.
- →Overall, the company expects stronger momentum with product portfolio expansion and increased commercialization in FY '27.
Key Metrics
Frequently Asked Questions
What were Sanjivani Paranteral Ltd Q4 FY26 results?
FY'27 total revenue guidance: INR 80-85 crores from base business; INR 60-65 crores from Pune IV plant. For FY'27, base business EBITDA margins are expected in the range of 15.5% to 16.5%, with anticipated recovery from Q1 onwards after March shipment disruptions.
What is Sanjivani Paranteral Ltd share price analysis?
Sanjivani Paranteral Ltd currently shows a neutral. The stock trades at a P/E of 35.2 with a market cap of ₹235 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sanjivani Paranteral Ltd planning capital expenditure?
The company has recently commissioned a new IV fluid infusion plant in Pune, which started commercial production in December 2025.
Keep Sanjivani Paranteral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.